Medlab Clinical (ASX: MDC) Share Price and News

Price

$6.60

Movement

( )

as at 3 Mar - Closed (20 mins delayed)

52 Week Range

-

 
1 Year Return

0.0

Medlab Clinical Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

$6.60

Day Change

( )

52 Week Range

-

Yesterday's Close

$6.60

Today's Open

Days Range

-

Volume

0

Avg. Volume (1 month)

0

Turnover

$0

as at 3 Mar - Closed

Medlab Clinical (ASX: MDC)
Latest News

a woman
Investing

Here are 2017's best performing ASX pot stocks

Australia’s pot stocks have been a hot topic this year. And some have proved very lucrative for shareholders.

Read more »

a woman
Investing

Here's Medlab Clinical Ltd's 'world first' plan to test cannabis on Sydney patients

The Medlab Clinical Ltd (ASX:MDC) plans to test cannabis at Royal North Shore Hospital. And investors seem to think that’s…

Read more »

MDC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
28th Feb 2025 2025-02-28T09:20:07 Removal from Official ListYesNo9:20am1547k
14th Feb 2025 2025-02-14T09:16:05 Results of Meeting 2024YesNo9:16am296k
14th Feb 2025 2025-02-14T09:15:40 Results of Meeting 2023YesNo9:15am297k
3rd Feb 2025 2025-02-03T14:08:11 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo2:08pm6353k
22nd Jan 2025 2025-01-22T16:20:01 Long Term Suspended EntitiesYesNo4:20pm8206k
10th Jan 2025 2025-01-10T16:08:40 Notice of Annual General Meeting/Proxy FormYesNo4:08pm13408k
10th Jan 2025 2025-01-10T16:08:00 Notice of General Meeting/Proxy FormYesNo4:08pm15423k
13th Dec 2024 2024-12-13T09:54:23 Response to Appendices 3X and 3Z QueryYesNo9:54am3812k
4th Dec 2024 2024-12-04T14:59:09 Final Director's Interest NoticeYesNo2:59pm2162k
4th Dec 2024 2024-12-04T14:58:34 Initial Director's Interest NoticeYesNo2:58pm2200k

About Medlab Clinical

Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. It operates through the Nutraceutical Sales and Pharmaceutical Research segments. Its products include BifidoBiotic, BioClean, Biotic Jnr., GastroDaily, Lactoferrin Enhanced, Manuka-C, NanoCelle, NeuroActiv, NRGBiotic, and ORSBiotic. The company was founded by Sean Hall on June, 2012 and is headquartered in Botany, Australia.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Tim Walker Non-Executive Director Mar 2024
Mr Walker is a corporate finance professional with experience in originating, managing, and leading resource-focused transaction. Specialising in M&A transactions across the Canadian and Australian markets, IPOs, and equity and debt financing solutions. Tim's past directorships with exploration companies have provided him with experience across commodity groups, including lithium exploration, rare earth and niobium hosted carbonatite deposits, whilst also having experience transacting on iron ore and base metal projects.
Mr Edmond Tan Non-Executive Director Mar 2024
Mr Tan is a financial services professional with over 10 years' experience in roles which include Private Wealth Management, Family Office, and Structured Finance. In addition, he was involved in the establishment of a mid-market private equity joint venture fund with a focus on foreign investment into Australia. Currently, Mr Tan is a Director of Regenerate Pty Ltd a rare earth magnet recycling technology based in Houston, Texas. He is also the Australian Representative for Obsidian Global Partners LLC, a structured financier for ASX listed companies.
Mr Joshua David Light Non-Executive Director Nov 2024
Mr Light is a corporate finance with broad expertise in investment banking and corporate advisory, particularly within the mining and resources sector. He has managed and facilitated numerous M&A transactions and capital raisings across primary and secondary markets in Australia and North America. Josh brings a understanding of base and critical metals and has coordinated various resource acquisitions at the junior market level.
Mr Kerem Kaya Chief Financial OfficerCompany Secretary May 2021
-
Kerem Kaya Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Sean Michael Hall 389,041 17.04%
Farjoy Pty Ltd 205,663 9.01%
HSBC Custody Nominees (Australia) Limited 88,229 3.86%
UBS Nominees Pty Ltd 85,316 3.74%
Fit Investments Pty Ltd Hallab Investment A/C 75,563 3.31%
Realm Group Pty Limited 54,705 2.40%
Citicorp Nominees Pty Limited 49,798 2.18%
Mr Drew Anthony Townsend Townsend Family A/C 37,038 1.62%
Richard Albarran Albarran Family No 2 A/C 37,038 1.62%
United Trolley Collections P/L 32,970 1.44%
BNP Paribas Nominees Pty Ltd Ib Au Noms Retailclient 30,272 1.33%
Mr Michael Jack Hall & Mrs Elizabeth Ann Jones Hall Jones Super Fund A/C 29,820 1.31%
Netwealth Investments Limited Wrap Services A/C 20,186 0.88%
Villamagna Inc 20,000 0.88%
BNP Paribas Noms Pty Ltd 17,164 0.75%
Daniel P Moses (Nominees) Pty Limited Daniel Moses Family A/C 16,667 0.73%
Acron Holdings Pty Limited Acron Super Fund A/C 16,181 0.71%
Kenney Family Investments Pty Ltd Kenney Family Account 15,295 0.67%
Assumo (Nominees) Pty Ltd Assumo S/Fund A/C 13,334 0.58%
D J Fairfull Pty Ltd Fairfull Super Fund A/C 12,651 0.55%

Profile

since

Note